Will the new administration pursue changes to the recent prescription drug reform? 

While certainly controversial one of the Biden administration’s legislative pieces is the Inflation Reduction Act. The law contained important reforms to Medicare’s Part D prescription drug coverage that protects seniors who experience high drug costs for serious illnesses and chronic diseases. It capped out-of-pocket spending at $3,300 in 2024, and the final step is a $2,000 cap beginning in 2025. It also caps the cost of insulin for Medicare enrollees at $35 per month, along with other cost-saving measures. 

Any Trump administration effort to repeal those protections would meet with stiff resistance. Project 2025 does call for repealing the provision of the Inflation Reduction Act that empowered Medicare to negotiate drug prices with pharmaceutical companies. That provision is tied directly to the new cap, since Medicare expects to recoup some of the higher cost of covering seniors through negotiated savings.  So perhaps a carve out of sorts may be appropriate.  Up next?  Will the new administration attempt to roll back the Affordable Care Act?